Edition:
United Kingdom

Jazz Pharmaceuticals PLC (JAZZ.OQ)

JAZZ.OQ on NASDAQ Stock Exchange Global Select Market

140.56USD
14 Dec 2018
Change (% chg)

-- (--)
Prev Close
$140.56
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
199,006
52-wk High
$183.96
52-wk Low
$130.15

Latest Key Developments (Source: Significant Developments)

Jazz Pharmaceuticals Announces Q3 2018 Financial Results
Tuesday, 6 Nov 2018 

Nov 6 (Reuters) - Jazz Pharmaceuticals PLC ::JAZZ PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS.QTRLY TOTAL REVENUES INCREASED 14% TO $469 MILLION.QTRLY GAAP DILUTED EPS OF $2.41.QTRLY ADJUSTED DILUTED EPS OF $3.58.QTRLY XYREM PRODUCT SALES INCREASED 18% TO $357 MILLION.AS OF SEPTEMBER 30, 2018, CASH, CASH EQUIVALENTS AND INVESTMENTS WERE $1.1 BILLION.JAZZ PHARMACEUTICALS - SEES 2018 REVENUE $1,860 MILLION - $1,900 MILLION.Q3 EARNINGS PER SHARE VIEW $3.32, REVENUE VIEW $482.6 MILLION -- THOMSON REUTERS I/B/E/S.JAZZ PHARMACEUTICALS - SEES 2018 NON-GAAP ADJUSTED NET INCOME PER DILUTED SHARE $12.75 - $13.25.JAZZ PHARMACEUTICALS - SEES 2018 GAAP NET INCOME PER DILUTED SHARE $5.70 - $6.90.FY2018 EARNINGS PER SHARE VIEW $13.11, REVENUE VIEW $1.92 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Jazz Pharmaceuticals Announces FDA Approval Of Xyrem For Treatment Of Cataplexy
Monday, 29 Oct 2018 

Oct 29 (Reuters) - Jazz Pharmaceuticals PLC ::JAZZ PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF XYREM® (SODIUM OXYBATE) FOR THE TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS IN PEDIATRIC NARCOLEPSY PATIENTS.JAZZ PHARMACEUTICALS PLC - GETS FDA APPROVAL OF XYREM.  Full Article

Jazz Pharmaceuticals announces FDA approval of Xyrem (Sodium Oxybate) for the treatment of Cataplexy or excessive daytime sleepiness in pediatric narcolepsy patients
Monday, 29 Oct 2018 

Oct 29 (Reuters) - Jazz Pharmaceuticals PLC ::JAZZ PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF XYREM (SODIUM OXYBATE) FOR THE TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS IN PEDIATRIC NARCOLEPSY PATIENTS.  Full Article

U.S. FDA Says Approved Jazz Pharmaceutical's Narcolepsy Drug, Xyrem, For Pediatric Patients
Friday, 26 Oct 2018 

Oct 26 (Reuters) - U.S. Food and Drug Administration::U.S. FDA - APPROVED XYREM FOR TREATMENT OF CATAPLEXY AND EXCESSIVE DAYTIME SLEEPINESS IN PEDIATRIC PATIENTS WITH NARCOLEPSY.  Full Article

Vyxeos Receives Marketing Authorisation In EU For Treatment Of Certain Types Of High-Risk Acute Myeloid Leukaemia
Monday, 27 Aug 2018 

Aug 27 (Reuters) - Jazz Pharmaceuticals PLC ::VYXEOS® RECEIVES MARKETING AUTHORISATION IN THE EUROPEAN UNION FOR TREATMENT OF CERTAIN TYPES OF HIGH-RISK ACUTE MYELOID LEUKAEMIA.JAZZ PHARMACEUTICALS PLC - EUROPEAN COMMISSION APPROVAL EXTENDS TO ALL EUROPEAN UNION MEMBER STATES, AS WELL AS ICELAND, NORWAY AND LIECHTENSTEIN.JAZZ PHARMACEUTICALS -PHASE 3 STUDY MET ITS PRIMARY ENDPOINT AS VYXEOS DEMONSTRATED SUPERIOR IMPROVEMENT IN OVERALL SURVIVAL COMPARED TO 7+3 TREATMENT REGIMEN.  Full Article

Jazz Pharmaceuticals Announces Second Quarter 2018 Financial Results
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Jazz Pharmaceuticals PLC ::JAZZ PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 ADJUSTED EARNINGS PER SHARE $3.49.Q2 GAAP EARNINGS PER SHARE $1.50.Q2 REVENUE $500 MILLION VERSUS I/B/E/S VIEW $469.9 MILLION.Q2 EARNINGS PER SHARE VIEW $3.23 -- THOMSON REUTERS I/B/E/S.SEES FULL YEAR 2018 REVENUES $1,880 MILLION -$1,930 MILLION.SEES FULL YEAR 2018 NON-GAAP ADJUSTED NET INCOME PER DILUTED SHARE $12.75-$13.25.SEES FULL YEAR 2018 GAAP NET INCOME PER DILUTED SHARE $5.70-$6.90.FY2018 EARNINGS PER SHARE VIEW $13.09, REVENUE VIEW $1.90 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Jazz Pharmaceuticals And MD Anderson Cancer Center Collaborate To Evaluate Potential Treatment Options For Hematologic Malignancies
Monday, 6 Aug 2018 

Jazz Pharmaceuticals PLC ::JAZZ PHARMACEUTICALS AND MD ANDERSON CANCER CENTER COLLABORATE TO EVALUATE POTENTIAL TREATMENT OPTIONS FOR HEMATOLOGIC MALIGNANCIES.  Full Article

Jazz Pharmaceuticals Enters Into Agreement With Tersera Therapeutics For Prialt
Friday, 29 Jun 2018 

June 29 (Reuters) - Jazz Pharmaceuticals PLC ::JAZZ PHARMACEUTICALS ENTERS INTO AGREEMENT WITH TERSERA THERAPEUTICS LLC FOR PRIALT.JAZZ PHARMACEUTICALS PLC - DEAL FOR $80 MILLION IN CASH AT CLOSING.JAZZ PHARMACEUTICALS PLC - TERSERA WILL OFFER EMPLOYMENT POSITIONS TO A MAJORITY OF JAZZ EMPLOYEES DEDICATED TO PRIALT.  Full Article

Jazz Pharmaceuticals Announces FDA Acceptance Of Supplemental New Drug Application For Xyrem (Sodium Oxybate)
Wednesday, 27 Jun 2018 

June 27 (Reuters) - Jazz Pharmaceuticals PLC ::JAZZ PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF SUPPLEMENTAL NEW DRUG APPLICATION FOR XYREM® (SODIUM OXYBATE) TO TREAT CATAPLEXY AND EXCESSIVE DAYTIME SLEEPINESS IN PEDIATRIC NARCOLEPSY PATIENTS.PRESCRIPTION DRUG USER FEE ACT (PDUFA) GOAL DATE FOR AN FDA DECISION IS OCTOBER 27, 2018.  Full Article

Spark Therapeutics Says Entered Into Asset Purchase Agreement With Jazz Pharmaceuticals Ireland Ltd
Monday, 30 Apr 2018 

April 30 (Reuters) - Spark Therapeutics Inc ::SPARK THERAPEUTICS SAYS ENTERED INTO ASSET PURCHASE AGREEMENT WITH JAZZ PHARMACEUTICALS IRELAND LIMITED - SEC FILING.SPARK THERAPEUTICS - PURSUANT TO AGREEMENT CO AGREED TO SELL RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER.SPARK THERAPEUTICS - JAZZ WILL PAY CO $110 MILLION FOR PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER UPON CLOSING OF PURCHASE - SEC FILING.  Full Article

UPDATE 3-J&J unit to pay $360 mln to U.S. to resolve charity kickback probe

BOSTON, Dec 6 A Johnson & Johnson unit will pay the U.S. government $360 million to resolve an investigation into its financial support of a charity that helped Medicare patients cover out-of-pocket drug costs, the Justice Department said on Thursday.